• Japanese
  • Korean
  • Chinese
Cover Image

Regenerative Medicine Markets

Abstract

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

Methodology

The author of this report is a retired college professor with three decades of experience in teaching biochemistry, biotechnology, pharmacology, environmental biology and horticulture. The detailed study of this report is based mainly on the publications of primary research on regenerative medicine, as well as information from venture capital firms. For the publicly held companies, the annual reports, 10-K filings and financial reports were examined. Information available from the proprietary databases at Biotechnology Associates and from the private data stores of TriMark Publications was also used in preparing this report. Important data sources include American Heart Association, American Autoimmune Related Disease Association, American Burn Association, World Stem Cell Report 2011 and 2012, Swedish Governmental Agency for Innovative System (VINNOVA) and research centers from the U.S. universities. The market data given in this report are based on available market data from press releases and company annual reports. Company profiles were gathered from the annual reports, conference proceedings and Internet searches. The information set forth in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information, any omission or the results obtained by the use of such information.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects and Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMarks research in the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government affiliated trade releases, and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of the top-ranking companies in the industry.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. Scope of this Report
  • 1.3. Methodology
  • 1.4. Executive Summary

2. Regenerative Medicines: An Overview of Segments

  • 2.1. Tissue Engineering
    • 2.1.1. Tissue-Engineered Skin
    • 2.1.2. Tissue-Engineered Cartilage
    • 2.1.3. Tissue-Engineered Bone
    • 2.1.4. Tissue-Engineered Peripheral Nerves
    • 2.1.5. Tissue-Engineered Cornea
    • 2.1.6. Tissue-Engineered Blood Vessels
    • 2.1.7. Progress and Promises for Tissue Engineering Industry
      • 2.1.7.1. Key Positioning Strategies in Tissue Engineering Industry
      • 2.1.7.2. Tissue Engineering Industry Participants
      • 2.1.7.3. Tissue Engineering Firms by their Product Applications
      • 2.1.7.4. Number of TEFs Focused on Skin, Cartilage, Bone and Urological Products
      • 2.1.7.5. Number of Tissue Engineering Firms Focused on Cardiovascular Products
      • 2.1.7.6. Number of Tissue Engineering Firms Focused on Neurological Products
      • 2.1.7.7. Number of Tissue Engineering Firms Focusing on Pancreas, Liver and Kidney
      • 2.1.7.8. Tissue Engineering Firms Focused on Ophthalmic Products
      • 2.1.7.9. Tissue Engineering Firms Involved in Dental Products
      • 2.1.7.10. Number of TEFs Involved in Autologous and Allogenic Products
      • 2.1.7.11. Geographic Distribution of Tissue Engineering Firms in Major Markets
  • 2.2. Cell. Therapy
    • 2.2.1. Progress in Cell Therapy Product Research
    • 2.2.2. Commercially Available Cell Therapy Products
    • 2.2.3. Major Cell Therapy Companies
    • 2.2.4. Locations of Cell Therapy Companies
    • 2.2.5. Disease Focus by Cell Therapy
    • 2.2.6. Cell Therapy Products and Companies
      • 2.2.6.1. Autologous Structural Products for Cartilage, Skin, Bone, etc.
    • 2.2.7. Potential Patients for Cell Therapy in the U.S.
    • 2.2.8. Number of Patients Treated Between 1988 and 2010 by Cell Therapy
    • 2.2.9. Cell Therapy Pipeline
    • 2.2.10. Cell Therapy Clinical Trials by Indication
      • 2.2.10.1. Major Cell Therapy Clinical Trials for Diabetes
      • 2.2.10.2. Progress in Clinical Trials for Diabetes
      • 2.2.10.3. Estimated Completion Dates for Cell Therapy Clinical Trials in Diabetes
    • 2.2.11. Major Four Targeted Disease Conditions for Clinical Trials
    • 2.2.12. Commercial Success of Cell Therapies in Europe
    • 2.2.13. Deals in Cell Therapy, 2007-2011
    • 2.2.14. Commercial-Stage Cell Therapy Companies and Products
    • 2.2.15. Cell Therapy Clinical Trials in the U.K.
      • 2.2.15.1. Clinical Trials Involving Allogeneic vs. Autologous Products in the U.K.
      • 2.2.15.2. Cell Types Involved in the U.K. Clinical Trials
      • 2.2.15.3. U.K. Cell Therapy Clinical Trials by Indication
  • 2.3. Cell Culture Products
    • 2.3.1. Market for Reagents Used in Cell Culture
    • 2.3.2. Cell Culture Media
    • 2.3.3. Market for Sera Used in Cell Culture
      • 2.3.3.1. Suppliers of Culture Media and Reagents
      • 2.3.3.2. In Vitro Test Kits
      • 2.3.3.3. Suppliers of Cells and Tissues
      • 2.3.3.4. Equipment for Stem Cell Research
      • 2.3.3.5. Computer Software for Stem Cell Research
  • 2.4. Scaffolding Biomaterials
  • 2.5. Growth Factors

3. Regenerative Medicine: The Next Evolution of Medical Treatment

  • 3.1. Scope of this Chapter
  • 3.2. Need for Regenerative Medicine
  • 3.3. Current State of Regenerative Medicines
  • 3.4. Future of Regenerative Medicine
    • 3.4.1. Number of Products in Pipeline
  • 3.5. Projected Timeline for Regenerative Medicine
  • 3.6. Selected Regenerative Medicine Products in the Market
    • 3.6.1. Medtronic's Infuse Bone Graft and LT-Cage Device
    • 3.6.2. Genzyme's Corticel
    • 3.6.3. OP-1 from Stryker
    • 3.6.4. Osteocel from Osyris/Nuvasive
    • 3.6.5. Spinal Implants from RTI Biologics
    • 3.6.6. Apligraf from Organogenesis
    • 3.6.7. Dermograft from Advanced BioHealing
    • 3.6.8. Integra's Bilayer Matrix for Wound Dressing
    • 3.6.9. Alloderm from LifeCell
    • 3.6.10. Celution from Cytori Therapeutics
    • 3.6.11. Other Products of Importance in Regenerative Medicine
    • 3.6.12. Tissue-Engineered Wound Healing Products
      • 3.6.12.1. Oasis
      • 3.6.12.2. Permacol
      • 3.6.12.3. EZ-Derm
      • 3.6.12.4. Matriderm
      • 3.6.12.5. TransCyte
      • 3.6.12.6. ICX-SKN
      • 3.6.12.7. OrCel
      • 3.6.12.8. Epicel
      • 3.6.12.9. Myskin
      • 3.6.12.10. VCT01
    • 3.6.13. ICX-TRC-Hair Regeneration Therapy
    • 3.6.14. Cartilage Regeneration
      • 3.6.14.1. Novocart
      • 3.6.14.2. BioSeed-C
      • 3.6.14.3. BioSeed-Oral Bone
      • 3.6.14.4. Chondrotissue
      • 3.6.14.5. co.don Chondrotransplant
      • 3.6.14.6. co.don Chondrotransplant DISC
      • 3.6.14.7. co.don Chondrosphere
      • 3.6.14.8. co.don Osteotransplant DENT
      • 3.6.14.9. MACI Implant
      • 3.6.14.10. Cartilink-3
      • 3.6.14.11. Accell Evo3 Demineralized Bone Matrix
      • 3.6.14.12. OsSatura BCP
    • 3.6.15. Mozobil
  • 3.7. Clinical Milestones in RM Sector, 2011-2012
    • 3.7.1. GINTUIT (March 2012)
    • 3.7.2. Ixmyelocel-T (February 2012)
    • 3.7.3. Autologous CD34+ Stem Cells (February 2012)
    • 3.7.4. HuCNS-SC (February 2012)
    • 3.7.5. DeNovo ET (February 2012)
    • 3.7.6. Retinal Pigment Epithelium Cells (January 2012)
    • 3.7.7. AMR-001 (January 2012)
    • 3.7.8. Avance Nerve Graft (January 2012)
    • 3.7.9. Adipose-Derived Stem Cells to Treat Myocardial Ischemia (January 2012)
    • 3.7.10. T-Cells Resistant to HIV (January 2012)
    • 3.7.11. Tissue-Engineered Windpipe (November 2011)
    • 3.7.12. Revascor (November 2011)
    • 3.7.13. ReN001 Stem Cell Therapy (September 2011)
    • 3.7.14. HP802-247 Allogeneic Cell Suspension for Leg Ulcers (August 2011)
    • 3.7.15. ALD-301 for Critical Limb Ischemia (May 2011)
    • 3.7.16. JVS-100 for Heart Failure (April 2011)
    • 3.7.17. MultiStem for Ulcerative Colitis (March 2011)
    • 3.7.18. HuCNS-SC Human Neural Stem Cells (March 2011)
  • 3.8. Accelerated Pace of Deals in RM Sector
    • 3.8.1. Acquisitions and Partnerships
      • 3.8.1.1. Shire's Acquisition of Advanced BioHealing, Inc. (May 2011)
      • 3.8.1.2. Terumo Americas Holding's Acquisition of Harvest Technologies (April 2011)
      • 3.8.1.3. Sanofi's Acquisition of Genzyme Corporation (February 2011)
      • 3.8.1.4. NeoStem's Acquisition of Progenitor Cell Therapy, LLC (January 2011)
      • 3.8.1.5. Strategic Alliance between Mesoblast and Cephalon, Inc. (December 2011)
    • 3.8.2. Notable Financings
      • 3.8.2.1. Financing to AlloCure, Inc. (April 2012)
      • 3.8.2.2. Financing to Promethera Biosciences (March 2012)
      • 3.8.2.3. Financing to In Vivo Therapeutics Holdings Corp. (February 2012)
      • 3.8.2.4. Financing to Organovo (March 2012)
      • 3.8.2.5. Financing to Cytomedix, Inc. (February 2012)
      • 3.8.2.6. Financing to Fate Therapeutics, Inc. (May 2011)
      • 3.8.2.7. Financing to Cellular Dynamics International, Inc. (April 2011)
      • 3.8.2.8. Financing to Cytori Therapeutics (December 2010)
      • 3.8.2.9. Overview of Capital Formation in RM Industry

4. Recent Advances in Regenerative Medicine and Stem Cell Research

  • 4.1. Bioengineered Autologous Vein
  • 4.2. Stem Cell Treatment for Spinal Cord Injury
  • 4.3. Repairing Damaged Retina
  • 4.4. A Possible Cure for Deafness
  • 4.5. Clinical Trials for Stem Cell Therapies for CNS Disorders by StemCells, Inc.
  • 4.6. First Clinical Use of Bioengineered Vascular Graft Made from Autologous Stem Cells
    • 4.6.1. Recent Developments in Stem Cell Therapy in Cardiology
    • 4.6.2. Recent Developments in Acute MI
    • 4.6.3. Chronic Ischemic Cardiomyopathy and Heart Failure
    • 4.6.4. Stem Cells and Neurodegenerative Diseases
  • 4.7. Disease Modeling: The Use of Inducible Cells
    • 4.7.1. Modeling Disease with iPS Cells
    • 4.7.2. Modeling Disease with Direct Neuronal Conversion
  • 4.8. Stem Cell Transplants
    • 4.8.1. Recent Developments in Ophthalmologic Stem Cell Transplantation Therapies
    • 4.8.2. Stem Cell Types for Eye Disease Clinical Trials
      • 4.8.2.1. Pluripotent Stem Cells
      • 4.8.2.2. Neural Stem Cells
      • 4.8.2.3. RPE Stem Cells
      • 4.8.2.4. Limbal Stem Cells
      • 4.8.2.5. Umbilical Cord Stem Cells
      • 4.8.2.6. Bone Marrow Stem Cells
      • 4.8.2.7. Pluripotent Stem Cells for Retinal and RPE Degeneration
      • 4.8.2.8. Patch of hESC-Derived RPE Monolayer
      • 4.8.2.9. Patient-Derived RPE
      • 4.8.2.10. NSCs for AMD
      • 4.8.2.11. UCSCs for RP and AMD
      • 4.8.2.12. Bone Marrow Stem Cells for Photoreceptor Diseases
      • 4.8.2.13. Corneal Repair
      • 4.8.2.14. Bioengineered Eye Tissues
  • 4.9. Regenerative Strategies in the Treatment of Diabetes
    • 4.9.1. Cell-Based Therapy for Diabetes
    • 4.9.2. Embryonic Stem Cells and Induced Pluripotent Cells

5. Stem Cell Industry Highlights, 2012

  • 5.1. Business Development
  • 5.2. Clinical Trials
  • 5.3. Market Authorization
  • 5.4. Regulations
  • 5.5. Capital Market and Finances
  • 5.6. Investments in Xeno-Cell Therapy
  • 5.7. Collaborations in Stem Cell Science
    • 5.7.1. California Institute for Regenerative Medicine (CIRM)
    • 5.7.2. The International Translational Regenerative Medicine Center

6. Regenerative Medicines: A Brief Update from Selected Countries

  • 6.1. U.S.
    • 6.1.1. Key Institutions
      • 6.1.1.1. California Institute for Regenerative Medicine
      • 6.1.1.2. The New York Stem Cell Foundation
      • 6.1.1.3. NIH Center for Regenerative Medicine
    • 6.1.2. Innovative Company
      • 6.1.2.1. Aastrom Biosciences
  • 6.2. Canada
    • 6.2.1. Key Institutions
      • 6.2.1.1. Institute of Biomaterials & Biomedical Engineering, University of Toronto
      • 6.2.1.2. Terry Fox Research Institute
      • 6.2.1.3. Institute for Research in Immunology and Cancer, University of Montreal
    • 6.2.2. Innovative Companies
      • 6.2.2.1. Northern Therapeutics
      • 6.2.2.2. Octane Biotech
  • 6.3. U.K.
    • 6.3.1. Key Institutions
      • 6.3.1.1. Loughborough University
      • 6.3.1.2. U.K. Stem Cell Foundation
      • 6.3.1.3. University College, London
    • 6.3.2. Innovative Companies
      • 6.3.2.1. Intercytex
      • 6.3.2.2. Azellon Cell Therapeutics
      • 6.3.2.3. Cell Medica
  • 6.4. Sweden
    • 6.4.1. Key Institutions
      • 6.4.1.1. Karolinska Institutet
      • 6.4.1.2. The University of Lund
    • 6.4.2. Innovative Companies
      • 6.4.2.1. Vitrolife
      • 6.4.2.2. Cellartis
      • 6.4.2.3. Biolamina
  • 6.5. Brazil
    • 6.5.1. Key Institutions
      • 6.5.1.1. Universidade de SaoPaulo
      • 6.5.1.2. Fiocruz and Hospital Sao Rafael
      • 6.5.1.3. Universidade Federal do Rio de Janeiro
      • 6.5.1.4. Pontificia Universidade Catolica do Parana
    • 6.5.2. Innovative Company
      • 6.5.2.1. Excellion & CellPraxys

7. Market Analysis for Regenerative Medicine Sector

  • 7.1. Scope of this Chapter
  • 7.2. Opportunities for RM Products
  • 7.3. Commercial RM Products
    • 7.3.1. Leading Commercial Cell Therapy Products
    • 7.3.2. FDA Approved Cell-Based Products
    • 7.3.3. Growth Spurt by Regenerative Medicine (RM)
  • 7.4. Global Market for Tissue-Engineered Products
    • 7.4.1. Tissue Engineering and Stem Cell Industry
  • 7.5. Market for Stem Cell Therapy in Cardiology
  • 7.6. Market for RM Products in Orthopedics
    • 7.6.1. No Strong Alternatives for Medtronic's INFUSE
    • 7.6.2. Demineralized Bone Matrix (DBM)
    • 7.6.3. The Unproven Stem Cells in Orthopedics
    • 7.6.4. Future of Bone Replacement Market
  • 7.7. Global RM Market for Neurology Products
  • 7.8. Market for RM Dental Products
  • 7.9. Market for RM Cancer Products
  • 7.10. RM Market for Urology Products
  • 7.11. Global Market for Skin Products
  • 7.12. Overall Global RM Market
  • 7.13. U.S. Market for Tissue-Engineered Skin
  • 7.14. U.S. RM Market for Orthopedic/Spine Products
  • 7.15. U.S. RM Market for Nerve Repair Products
  • 7.16. U.S. RM Market for Cardiovascular and Stroke Products
  • 7.17. U.S. Market for Anti-Inflammatory RM Products
  • 7.18. U.S. Market for RM Products in Diabetes
  • 7.19. Overall U.S. Regenerative Medicine Market
    • 7.19.1. U.S. RM Market by Segment

8. Stem Cell Industry

  • 8.1. Global Market for Stem cells
  • 8.2. Stem Cell Use in the U.S.
    • 8.2.1. Autologous Stem Cell Use in the U.S.
    • 8.2.2. U.S. Stem Cell Market Overview
      • 8.2.2.1. Potential U.S. Population for Cell-Based Therapies
    • 8.2.3. U.S. Market for Stem cells
  • 8.3. European Market for Stem Cells
    • 8.3.1. Autologous and Allogeneic Cell Therapy Companies in Europe
  • 8.4. Asia-Pacific Market for Stem Cells
  • 8.5. Autologous Cell Therapy
    • 8.5.1. Commercially Available Autologous Treatments
      • 8.5.1.1. Autologous Cell Therapy for Alzheimer's disease
      • 8.5.1.2. Autologous Cell Therapy for Multiple Sclerosis
      • 8.5.1.3. Autologous Cell Therapy for Wound Healing
      • 8.5.1.4. Autologous Therapy for Cosmetic Surgery

9. Business Models and Requirements for a Successful Regenerative Medicine Industry

  • 9.1. Scope of this Chapter
  • 9.2. Business Models in Regenerative Medicine
    • 9.2.1. Current Model for Autologous Cell Therapies
    • 9.2.2. Current Models for Allogeneic Cell Therapies
  • 9.3. Key Factors for Successful Business Models for Cell Therapies
  • 9.4. Requirements for Commercial Manufacturing of Cell Therapy Products
    • 9.4.1. Elements of Commercial Manufacturing
      • 9.4.1.1. Regulatory Requirements
      • 9.4.1.2. Manufacturing Process Scale
      • 9.4.1.3. In-House Manufacturing
      • 9.4.1.4. Contract Manufacturing: Commercial and Academic

10. Company Profiles

  • 10.1. Aastrom Biosciences, Inc.
    • 10.1.1. Aastrom's Cellular Therapy and Ixmyelocel-T
      • 10.1.1.1. Advantages of Patient's Bone Marrow and Ixmyelocel-T
    • 10.1.2. Aastrom's Clinical Trials
      • 10.1.2.1. REVIVE-CLI
      • 10.1.2.2. RESTORE-CLI
  • 10.2. Advanced Cell Technology, Inc. (ACT)
    • 10.2.1. ACT's Human ES Cell Programs
    • 10.2.2. ACT's Human Embryonic Stem Cell Technologies
    • 10.2.3. ACT's Cell Therapy Research Program
      • 10.2.3.1. Retinal Pigment Epithelium Program
      • 10.2.3.2. Hemangioblast Program
      • 10.2.3.3. Adult Stem Cell Program
    • 10.2.4. ACT's Intellectual Property
  • 10.3. AlloCure, Inc.
    • 10.3.1. AlloCure's Technology
    • 10.3.2. AlloCure's Clinical Trials
      • 10.3.2.1. Acute Kidney Injury
      • 10.3.2.2. Epidemiological Study of AKI
      • 10.3.2.3. Phase I Clinical Trial in AKI
      • 10.3.2.4. Phase II Clinical Trial in AKI
  • 10.4. Altrika Ltd.
    • 10.4.1. Myskin
    • 10.4.2. Cryoskin
  • 10.5. American Type Culture Collection, Inc. (ATCC)
    • 10.5.1. ATCC's Cell Lines and Hybridomas
    • 10.5.2. ATCC's Media, Sera and Reagents
    • 10.5.3. MTT Cell Proliferation Assay
    • 10.5.4. XTT Cell Proliferation Assay Kit
    • 10.5.5. Universal Mycoplasma Detection Kit
    • 10.5.6. DNA and RNA
    • 10.5.7. STR Profile Database
    • 10.5.8. hTERT Immortalized Cell Lines
    • 10.5.9. Embryonic Stem Cell Products
    • 10.5.10. Bacteria and Phages
    • 10.5.11. Fungi and Yeast
    • 10.5.12. Protozoa and Algae
    • 10.5.13. Viruses and Related Reagents
    • 10.5.14. Microbial DNA and RNA
    • 10.5.15. ATCC's Tissue Biology Products
  • 10.6. Avita Medical Limited
    • 10.6.1. ReCell
  • 10.7. Amorcyte, LLC
    • 10.7.1. AMR-001
  • 10.8. Ars Arthro AS
    • 10.8.1. CaReS
    • 10.8.2. Fibrocell
    • 10.8.3. Fibroplus
  • 10.9. Axiogenesis AG
    • 10.9.1. Human iPS Cell-Derived Cardiomyocytes
    • 10.9.2. Murine Cardiomyocytes ES
    • 10.9.3. Murine Cardiomyocytes iPS
    • 10.9.4. Murine Endothelial Cells
    • 10.9.5. Murine Smooth Muscle Cells
  • 10.10. AxoGen, Inc.
    • 10.10.1. Avance Nerve Graft
    • 10.10.2. AxoGuard Nerve Protector
    • 10.10.3. AxoGuard Nerve Connector
  • 10.11. Bellicum Pharmaceuticals, Inc.
    • 10.11.1. Bellicum's Technology
    • 10.11.2. Bellicum's Pipeline
  • 10.12. BetaStem Therapeutics, Inc.
    • 10.12.1. BetaStem's Technology
  • 10.13. Bioheart, Inc.
    • 10.13.1. MyoCell
    • 10.13.2. MyoCell SDF-1
    • 10.13.3. MyoCath
    • 10.13.4. LipiCell
  • 10.14. Biomet, Inc.
    • 10.14.1. Endobon Xenograft Granules
    • 10.14.2. RegenerOss Allograft
    • 10.14.3. Ground Cancellous Bone
  • 10.15. BioMimetic Therapeutics, Inc.
    • 10.15.1. Augment Bone Graft
    • 10.15.2. Augmatrix Biocomposite Bone Graft
  • 10.16. BioTissue Technologies AG
    • 10.16.1. BioSeed-C
    • 10.16.2. Chondrotissue
    • 10.16.3. BioSeed-Oral Bone
  • 10.17. Biovest International, Inc.
    • 10.17.1. Autovaxid
    • 10.17.2. Xcellerator
    • 10.17.3. Maximizer
    • 10.17.4. Minimax
  • 10.18. BrainStorm Cell Therapeutics, Inc.
    • 10.18.1. NurOwn
  • 10.19. California Stem Cell, Inc.
    • 10.19.1. Clinical Pipeline
      • 10.19.1.1. MotorGraft
      • 10.19.1.2. Cancer Stem Cell
    • 10.19.2. Cell Products
      • 10.19.2.1. MotorPlate and MotorVial
      • 10.19.2.2. NeuroPlate and NeuroVial
      • 10.19.2.3. OPCVial
      • 10.19.2.4. HepatoPlate
    • 10.19.3. Cell Culture Products
      • 10.19.3.1. StemBlast
      • 10.19.3.2. MotorBlast
      • 10.19.3.3. NeuroBlast
      • 10.19.3.4. OPC Media
      • 10.19.3.5. Cellular Transplant Solution
  • 10.20. Cardio3 Biosciences SA
    • 10.20.1. Products Pipeline
      • 10.20.1.1. C3BS-CQR-1 (C-Cure)
      • 10.20.1.2. Positive Phase II Results for C-Cure
      • 10.20.1.3. C3BS-CQR-1 (Protein)
      • 10.20.1.4. C-CATHez (Medical Device)
  • 10.21. Cellartis AB (Cellectis)
    • 10.21.1. iPS Engineering Hub
    • 10.21.2. Hepatocytes hiPS-HEP
    • 10.21.3. Cardiomyocyte Clusters hES-CMC
    • 10.21.4. Stem Cell Culture System DEF-CS
  • 10.22. CellSeed, Inc.
    • 10.22.1. Epithelial Cell Sheet for Corneal Regeneration
    • 10.22.2. Regenerated Cardiac Patch
    • 10.22.3. Epithelial Cell Sheet for Esophageal Regeneration
    • 10.22.4. Cell Sheet for Periodontal Regeneration
    • 10.22.5. Regenerated Cartilage Sheet
  • 10.23. Cellular Dynamics International, Inc.
    • 10.23.1. iCell Cardiomyocytes
    • 10.23.2. iCell Endometrial Cells
    • 10.23.3. iCell Hepatocytes
    • 10.23.4. iCell Neurons
    • 10.23.5. MyCell Products
  • 10.24. Chromocell Corporation
    • 10.24.1. Chromovert Technology
    • 10.24.2. Chromovert Applications
      • 10.24.2.1. Pain Relief
      • 10.24.2.2. Anxiety Treatments
      • 10.24.2.3. Respiratory Disorders
  • 10.25. Cognate Bioservices, Inc.
    • 10.25.1. Process Development
    • 10.25.2. Regulatory Services
    • 10.25.3. Assay Development
    • 10.25.4. Preclinical Services
    • 10.25.5. Stem Cell Services
  • 10.26. Cook Biotech, Inc.
    • 10.26.1. Cook's Technology
    • 10.26.2. Biodesign Dural Graft
    • 10.26.3. Dynamatrix Extracellular Membrane
    • 10.26.4. tarSys
    • 10.26.5. Oasis Wound Matrix
    • 10.26.6. Biodesign Staple Line Reinforcement
    • 10.26.7. Biodesign Hiatal Hernia Graft
    • 10.26.8. CorMatrix ECM
    • 10.26.9. ECM for Cardiac Tissue Repair
    • 10.26.10. Biodesign Incision Graft
    • 10.26.11. Biodesign Inguinal Hernia Graft
    • 10.26.12. Biodesign Parastomal Reinforcement Graft
    • 10.26.13. Biodesign Umbilical Hernia Graft
    • 10.26.14. Biodesign Anterior Pelvic Floor Graft
    • 10.26.15. Biodesign Fistula Plug
    • 10.26.16. LIFT with Biodesign
    • 10.26.17. Biodesign Posterior Pelvic Floor Graft
    • 10.26.18. Biodesign Peyronie's Repair Graft
    • 10.26.19. Biodesign Tension-Free Urethral Sling
  • 10.27. Cytomedix, Inc.
    • 10.27.1. Cytomedix's AutoloGel System
      • 10.27.1.1. The Working of AutoloGel System
      • 10.27.1.2. Balancing Effect of AutoloGel System
      • 10.27.1.3. Formulation of AutoloGel System
    • 10.27.2. Cytomedix's Angel PRP
  • 10.28. Cytonet, LLC
    • 10.28.1. Cytonet's Liver Cell Therapy
    • 10.28.2. SELICA III Clinical Trial
  • 10.29. Cytori Therapeutics, Inc.
    • 10.29.1. Cytori's Commercial Activities and Markets
    • 10.29.2. Cytori's Pipeline
      • 10.29.2.1. Celution System for Cardiovascular Disease
      • 10.29.2.2. Other Applications of Celution System
      • 10.29.2.3. PureGraft
      • 10.29.2.4. StemSource
  • 10.30. DanDrit Biotech A/S
    • 10.30.1. Dendritic Cell
      • 10.30.1.2. Colorectal Cancer Trial Phase II in Singapore
      • 10.30.1.3. Non-Small-Cell Lung Cancer, Phase II
  • 10.31. Fibrocell Science, Inc.
    • 10.31.1. Fibrocell's Technology
    • 10.31.2. Pipeline
  • 10.32. Forticell Bioscience, Inc.
    • 10.32.1. OrCel
  • 10.33. Gamida Cell Ltd.
    • 10.33.1. Gamida's Technology
      • 10.33.1.1. Copper Chelator Based Technology
      • 10.33.1.2. NAM Based Technology
      • 10.33.1.3. StemEx
      • 10.33.1.4. NiCord
      • 10.33.1.5. CordBridge
      • 10.33.1.6. NK Cell Product
  • 10.34. Harvest Technologies Corporation
    • 10.34.1. Smart PReP2 APC+
    • 10.34.2. SmartPReP 2 BMAC
  • 10.35. Histogenics Corporation
    • 10.35.1. NeoCart
    • 10.35.2. VeriCart
  • 10.36. Humacyte, Inc.
    • 10.36.1. Humacyte Grafts
  • 10.37. Integra Lifesciences Holdings Corporation
    • 10.37.1. Integra's Products Overview
    • 10.37.2. Integra's Orthopedics Product Portfolio
    • 10.37.3. Integra's Extremity Reconstruction Product Portfolio
      • 10.37.3.1. Skin and Wound
      • 10.37.3.2. Bone and Joint Fixation Devices and Instruments
      • 10.37.3.3. Lower Extremity Products
      • 10.37.3.4. Upper Extremity Products
      • 10.37.3.5. Bone Graft Substitutes for Extremity Reconstruction
      • 10.37.3.6. Nerve and Tendon
    • 10.37.4. Integra's Spine Product Portfolio
      • 10.37.4.1. Integrated Interbody Fusion Devices
      • 10.37.4.2. Minimally Invasive Solutions
      • 10.37.4.3. Deformity Correction
      • 10.37.4.4. Orthobiologics
      • 10.37.4.5. Integra's Research and Development in Regenerative Medicine
  • 10.38. Intercytex Ltd.
    • 10.38.1. VAVELTA
    • 10.38.2. Epidermolysis Bullosa
    • 10.38.3. Scar Contractures
    • 10.38.4. Acne Scarring
    • 10.38.5 International Stem Cell Corporation
    • 10.38.6. Therapeutic Programs
  • 10.39. iPierian, Inc.
    • 10.39.1. Technology
    • 10.39.2. Product Development
  • 10.40. Japan Tissue Engineering Co., Ltd.
    • 10.40.1. Autologous Cultured Epidermis
    • 10.40.2. Autologous Cultured Cartilage
    • 10.40.3. Autologous Cultured Corneal Epithelium
  • 10.41. Kensey Nash Corporation
    • 10.41.1. Medeor Matrix
    • 10.41.2. Meso BioMatrix Scaffold
    • 10.41.3. Epi-Guide Bioresorbable Barrier Matrix
    • 10.41.4. OsseoFit Porous Tissue Matrix
    • 10.41.5. Vitoss Scaffold Foam Products
  • 10.42. Kiadis Pharma B.V.
    • 10.42.1. Kiadis' Pipeline
      • 10.42.1.1. ATIR
      • 10.42.1.2. Reviroc
      • 10.42.1.3. Rhitol
  • 10.43. Living Cell Technologies Limited (LCT)
    • 10.43.1. Diabecell
    • 10.43.2. Ntcell
  • 10.44. Life Cell Corporation
    • 10.44.1. AlloDerm
    • 10.44.2. Cymetra Micronized AlloDerm Tissue
    • 10.44.3. Strattice Reconstructive Tissue Matrix
    • 10.44.4. SPY Elite System
  • 10.45. MaxCyte, Inc.
    • 10.45.1. MaxCytes Technology Platform
    • 10.45.2. Drug Discovery Applications
      • 10.45.2.1. GPCRs
      • 10.45.2.2. Ion Channels
    • 10.45.3. Antibody Production
    • 10.45.4. General Protein Production
    • 10.45.5. Viral Vector and VLP Production
    • 10.45.6. Insect Cell Transfection
    • 10.45.7. Cell Therapy
      • 10.45.7.1. Dendritic Cell Vaccines
      • 10.45.7.2. Regenerative Medicine
      • 10.45.7.3. Chimeric Antigen Receptor (CAR) Immunotherapy
  • 10.46. MediStem, Inc.
    • 10.46.1. Intellectual Property
      • 10.46.1.1. Method for Expansion of Stem Cells
      • 10.46.1.2. Compositions of Placentally-Derived Stem Cells for the Treatment of Cancer
      • 10.46.1.3. Transcatheter Tumor Immunoembolization
      • 10.46.1.4. Stem Cell Therapy for Cardiac Valvular Dysfunction
      • 10.46.1.5. Treatment of Erectile Dysfunction by Stem Cell Therapy
      • 10.46.1.6. Allogeneic Stem Cell Transplants in Non-Conditioned Recipients
      • 10.46.1.7. Stem Cell Mediated Treg Activation for Therapeutic Immune Modulation
      • 10.46.1.8. Cellular Therapy for Lower Back Pain
      • 10.46.1.9. Compositions and Methods of Stem Cell Therapy for Autism
      • 10.46.1.10. Stem Cell Therapy for Weight Loss
      • 10.46.1.11. Menstrual Blood Cellular Populations, Isolation, and Use Thereof
      • 10.46.1.12. Endometrial Derived Reparative/Regenerative Cells
      • 10.46.1.13. Treatment of Insulin Resistance and Diabetes
      • 10.46.1.14. Combination Treatment of Cardiovascular Disease
      • 10.46.1.15. Stem Cell Therapy for Autism
    • 10.46.2. Product Pipeline
      • 10.46.2.1. Endometrial Regenerative Cell Platform
      • 10.46.2.2. Angiostem Platform
      • 10.46.2.3. Tolerostem Platform
  • 10.47. Mesoblast Ltd.
    • 10.47.1. Revascor
    • 10.47.2. MPCs for Diabetics
    • 10.47.3. Bone Marrow Derived Allogeneic MPCs
    • 10.47.4. Macular Degeneration
    • 10.47.5. Diabetic Macular Edema
    • 10.47.6. Intervertebral Disc Repair Product
    • 10.47.7. Lumbar and Cervical Spinal Fusion Product
    • 10.47.8. Fracture Repair Product
    • 10.47.9. Arthritis Product
  • 10.48. MolMed S.p.A.
    • 10.48.1. MolMed's Technological Platforms
  • 10.49. NanoCor Therapeutics, Inc.
    • 10.49.1. Carfostin
  • 10.50. Neuralstem, Inc.
    • 10.50.1. Neuralstem's Technology Platforms: Stem Cells
    • 10.50.2. Pharmaceutical Compounds
    • 10.50.3. Neuralstem's Clinical Trials for Stem Cells
    • 10.50.4. Clinical Trials for Neuralstem's Pharmaceutical Compound
  • 10.51. NeuroNova AB
    • 10.51.1. Neurogenesis Qualifier
    • 10.51.2. NeuroNova's Projects
  • 10.52. Olympus Terumo Biomaterials Corp.
    • 10.52.1. OSferion60
    • 10.52.2. Terudermis
    • 10.52.3. OSferion
    • 10.52.4. Teruplug
    • 10.52.5. Bone Cream
  • 10.53. NewLink Genetics Corporation
  • 10.54. OncoMed Pharmaceuticals, Inc.
    • 10.54.1. OncoMed's Research on Cancer Stem Cells
    • 10.54.2. OncoMed's Platform
    • 10.54.3. OncoMed's Development Pipeline
  • 10.55. Opexa Therapeutics, Inc.
    • 10.55.1. T-Cell Platform
  • 10.56. Organogenesis, Inc.
    • 10.56.1. Apligraf
    • 10.56.2. Gintuit
  • 10.57. Orthovita, Inc.
    • 10.57.1. Vitoss
  • 10.58. Osiris Therapeutics, Inc.
    • 10.58.1. Osiris' Technologies
      • 10.58.1.1. Stem Cell Source
      • 10.58.1.2. Manufacturing Process
  • 10.59. Osteotech, Inc.
    • 10.59.1. MagniFuse
    • 10.59.2. Plexur P
    • 10.59.3. Plexur M
    • 10.59.4. FacetLinx Fusion Technology
    • 10.59.5. Grafton
    • 10.59.6. Xpanse Bone Inserts
    • 10.59.7. GraftCage TLX and GraftCage ACX
  • 10.60. Pervasis Therapeutics, Inc.
  • 10.61 Pluristem Therapeutics, Inc.
  • 10.62. Proneuron Biotechnologies, Inc.
    • 10.62.1. Spinal Cord Technology
  • 10.63. RegeneRx
    • 10.63.1. Tβ4 Peptide Research
  • 10.64. ReNeuron Group PLC
    • 10.64.1. ReN001
    • 10.64.2. ReN009
    • 10.64.3. ReNcell VM and ReNcell CX
  • 10.65. Revivicor, Inc.
    • 10.65.1. Xenotransplantation Technology
  • 10.66. SanBio, Inc.
    • 10.66.1. SanBio's Product Pipeline
      • 10.66.1.1. SB623
      • 10.66.1.2. SB618
      • 10.66.1.3. SB308
  • 10.67. Saneron CCEL Therapeutics, Inc.
    • 10.67.1. U-Cord Cell Program
    • 10.67.2. Sert-Cell Program
  • 10.68. Sangamo Biosciences, Inc.
    • 10.68.1. SB-728
    • 10.68.2. SB-313
    • 10.68.3. Hemophilia
  • 10.69. Stem Cell Authority Ltd.
    • 10.69.1. MIRACHYMAL Stem Cells
  • 10.70. StemCells, Inc.
    • 10.70.1. StemCells' Research Collaborations
      • 10.70.1.1. Stanford University and Stanford School of Medicine
      • 10.70.1.2. UC Irvine
      • 10.70.1.3. OHSU Casey Eye Institute
      • 10.70.1.4. McLaughlin Research Institute
    • 10.70.2. StemCells' Therapeutic Programs
    • 10.70.3. Cells and Cell Lines
    • 10.70.4. Cell Culture Products
    • 10.70.5. Antibody Detection Reagents
    • 10.70.6. Purified Whole Stem Cell Lysates
  • 10.71. Stemline Therapeutics, Inc.
    • 10.71.1. Cancer Stem Cells
    • 10.71.2. Stemline Therapeutics' Platform
  • 10.72. Stratetech Corporation
    • 10.72.1. Stratatech's Core Technology
  • 10.73. Synthecon, Inc.
    • 10.73.1. Rotary Cell Culture Systems
    • 10.73.2. Biofelt (Bioabsorbable Scaffold)
    • 10.73.3. Biomerix 3D Scaffolds
    • 10.73.4. RollerCell 40
  • 10.74. Tengion, Inc.
    • 10.74.1. Tengion's Scientific Platform
    • 10.74.2. Tengion's Pipeline
  • 10.75. TiGenics NV
    • 10.75.1. ChondroCelect
    • 10.75.2. CX601
    • 10.75.3. Cx611
    • 10.75.4. Cx621
  • 10.76. Tissue Genesis, Inc.
    • 10.76.1. Clinical Therapies from Tissue Genesis
      • 10.76.1.1. Icellator
      • 10.76.1.2. Adipase
  • 10.77. Thermogenesis Corp.
    • 10.77.1. AXP System
    • 10.77.2. MXP System
    • 10.77.3. Manual Systems
    • 10.77.4. Res-Q 60 BMC System
    • 10.77.5. BioArchive System
  • 10.78. ViaCyte, Inc.
    • 10.78.1. Technology Overview
  • 10.79. Vistagen Therapeutics, Inc.
    • 10.79.1. Vistagen's Technology
    • 10.79.2. CardioSafe 3D
    • 10.79.3. LiverSafe 3D
  • 10.80. Zen-Bio, Inc.

Appendix 1: Allogeneic vs. Autologous Stem Cell Therapy

  • Appendix 1.1: Manufacturing Process
  • Appendix 1.2: Cost Differential
  • Appendix 1.3: Donor Screening and Testing
  • Appendix 1.4: Release Testing
  • Appendix 1.5: Overall Analysis

INDEX OF FIGURES

  • Figure 2.1: Geographic Distribution of Tissue Engineering Firms in Major Markets
  • Figure 2.2: The Potential Uses of Embryonic Stem Cells
  • Figure 2.3: Progress of Cell Therapy Product Research, 2012
  • Figure 2.4: Commercially Available Cell Therapy Products, 2012
  • Figure 2.5: Disease Focus by Regenerative Medicine
  • Figure 2.6: Estimated Completion Dates for Stem Cell Based Clinical Trials Targeting Type 1 Diabetes, 2009-2015
  • Figure 2.7: Number of Clinical Trials by Targeted Condition, 2005-2011
  • Figure 2.8: Concentration of European Cell Therapy Firms, 2012
  • Figure 2.9: European Stem Cell Platforms by Cell Source
  • Figure 2.10: Autologous vs. Allogeneic Stem Cell Therapy Firms in Europe, 2012
  • Figure 2.11: Autologous and Allogeneic Somatic Cell Therapy Firms in Europe, 2012
  • Figure 2.12: Sponsors of Cell Therapy Clinical Trials in the U.K., 2012
  • Figure 2.13: Clinical Trials Involving Allogeneic vs. Autologous Cell Therapy Products in the U.K., 2012
  • Figure 2.14: Cell Types Involved in the U.K. Cell Therapy Clinical Trials, 2012
  • Figure 2.15: U.K. Cell Therapy Clinical Trials by Indication, 2012
  • Figure 2.16: Cell Culture Products Market by Segment, 2012
  • Figure 2.17: Market for Reagents Used in Cell Culture, 2012-2019
  • Figure 2.18: Market for Media Used in Cell Culture, 2012-2019
  • Figure 2.19: Market for Serum Used in Cell Culture, 2012-2019
  • Figure 5.1: CIRM's Grants for Disease Types by Funding Level, 2012
  • Figure 7.1: Commercially Available Regenerative Products
  • Figure 7.2: Global Market for Tissue Engineering Products, 2012-2019
  • Figure 7.3: Global RM Market for Cardiology and Vascular Products, 2012-2019
  • Figure 7.4: Alternatives for Medtronic's Infuse
  • Figure 7.5: Global Market for RM Products in Orthopedics, Musculoskeletal and Spine, 2012-2019
  • Figure 7.6: Global RM Market for Neurology Products, 2012-2019
  • Figure 7.7: Global RM Market for Dental Products, 2012-2019
  • Figure 7.8: Global Tissue Engineering and Cell Therapy Market for Cancer Products, 2012-2019
  • Figure 7.9: Global Market for RM Products in Urology, 2012-2019
  • Figure 7.10: Global Market for RM Products in Skin/Integument, 2012-2019
  • Figure 7.11: Global Tissue Engineering and Cell Therapy Market, 2012-2019
  • Figure 7.12: U.S. Market for Tissue Engineered Skin Replacement and Substitutes, 2012-2019
  • Figure 7.13: U.S. Market for RM Products in Orthopedic/Spine, 2012-2020
  • Figure 7.14: U.S. Market for RM Products in Nerve Repair, 2012-2020
  • Figure 7.15: U.S. Market for RM Products in Cardiovascular Therapies, 2012-2020
  • Figure 7.16: U.S. Market for RM Products in Anti-Inflammatory Therapies, 2012-2020
  • Figure 7.17: U.S. Market for RM Products in Diabetes, 2012-2020
  • Figure 7.18: U.S. Market for Regenerative Medicines, 2012-2020
  • Figure 7.19: U.S. Regenerative Medicine Market by Segment, 2020
  • Figure 8.1: Global Market for Stem Cell Products, 2012-2020
  • Figure 8.2: U.S. Market for Stem Cell Products, 2012-2020
  • Figure 8.3: Estimated U.S. Market for Stem Cell Therapy by Type, 2020
  • Figure 8.4: European Market for Stem Cell Products, 2012-2020
  • Figure 8.5: Number of Autologous and Allogeneic Cell Therapy Firms in Europe
  • Figure 8.6: Asia-Pacific Market for Stem Cells, 2012-2019
  • Figure 8.7: Global Autologous Cell Therapy Market, 2012-2019
  • Figure 9.1: Cell-Based Business Models
  • Figure 9.2: Current Autologous Business Models
  • Figure 9.3: Current Allogeneic Business Models
  • Figure 10.1: Aastrom's Cell Expansion Process

INDEX OF TABLES

  • Table 2.1: Commercially Available Bioengineered Skin Products
  • Table 2.2: A Partial List of Companies Offering Bioreactor Systems
  • Table 2.3: Number of Tissue Engineering Companies in the Five Focus Countries
  • Table 2.4: Number of Tissue Engineering Firms Developing Stem Cells Seeded to Scaffolds
  • Table 2.5: Number of Tissue Engineering Firms Focusing on Skin, Cartilage, Bone and Urological Products
  • Table 2.6: Number of Tissue Engineering Firms Focused on Cardiovascular Products
  • Table 2.7: Number of Tissue Engineering Firms Focusing on Neurological Products
  • Table 2.8: Number of Tissue Engineering Firms Focusing on Pancreas, Liver and Kidney
  • Table 2.9: Number of TE Firms Focused on Autologous and Allogenic Products
  • Table 2.10: Major Cell Therapy Companies
  • Table 2.11: Geographical Distribution of Cell Therapy Companies
  • Table 2.12: Cell Therapy Products on the Market
  • Table 2.13: Cell Therapy Products on the Market by Type and Application
  • Table 2.14: Potential Patients for Cell Therapy in the U.S.
  • Table 2.15: Number of Patients Treated with Cell Therapy Between 1988 and 2010
  • Table 2.16: Cell Therapy Pipeline, 2005-2011
  • Table 2.17: Number of Stem Cell Clinical Trials by Indication, 2012
  • Table 2.18: Major Cell Therapy Clinical Trials for Diabetes and Estimated Enrollment Targets, 2012
  • Table 2.19: Progress in Clinical Trials for Diabetes, 2012
  • Table 2.20: Cell Therapy Deals, 2007-2011
  • Table 2.21: Select Cell Therapy Products with FDA/EMA Regulatory Approval, 1998-2010
  • Table 2.22: Cell Therapy Companies and Products
  • Table 2.23: Cell Therapy Products Approved in South Korea
  • Table 2.24: Selected Suppliers of Culture Media and Reagents
  • Table 2.25: Selected Suppliers of In Vitro Test Kits
  • Table 2.26: Selected Suppliers of Cells and Tissues
  • Table 2.27: Selected Suppliers of Equipment for Stem Cell Research
  • Table 2.28: Selected Companies Offering Computer Software for Stem Cell Research
  • Table 3.1: Industry Participants in Regenerative Medicine
  • Table 3.2: Top Ten Regenerative Medicine Products in the Market
  • Table 3.3: Industry-Sponsored Active Cell Therapy Trials, 2007 and 2012
  • Table 4.1: Recently Published Stem Cell Therapy Clinical Trials for Ischemic Heart Disease
  • Table 5.1: CIRM Funding for Projects Moving Towards Disease Therapies, 2012
  • Table 5.2: List of CIRM Funded Institutions, 2012
  • Table 7.1: A Sampling of Leading Commercial Cell Therapy Products, 2012
  • Table 7.2: FDA-Approved Cell-Based Products, 1997-2012
  • Table 7.3: Ongoing and Reported Clinical Trials in Ischemic Heart Disease
  • Table 7.4: Human Skin Equivalents for Clinical Skin Replacements and Grafts
  • Table 7.5: Human Skin Models for Drug Permeability Tests and Toxicity Screening
  • Table 8.1: Cell Therapy Products Revenue, 2010-2011
  • Table 8.2: Market Capitalization of Public Stem Cell Companies, 2011 vs. 2010
  • Table 8.3: Potential U.S. Population for Cell-Based Therapies
  • Table 8.4: Non-Autologous and Autologous Skin Substitutes and Dermal Treatments for Other Applications
  • Table 9.1: The Required Elements of a Manufacturing Facility
  • Table 9.2: Cell Therapy CMO Qualification Audit: Points to Investigate
  • Table 10.1: ACT's Pipeline of Therapeutic Programs
  • Table 10.2: Patents Owned by ACT
  • Table 10.3: Patents Owned by ACT's Subsidiary Mytogen, Inc.
  • Table 10.4: Patents Licensed to ACT by the University of Massachusetts
  • Table 10.5: Bellicum's Pipeline
  • Table 10.6: Bioheart's Intellectual Property
  • Table 10.7: Cardio3 Biosciences' Products Pipeline
  • Table 10.8: Gamida's Pipeline Overview
  • Table 10.9: International Stem Cell Corporation's Therapeutic Programs
  • Table 10.10: Kiadis' Pipeline
  • Table 10.11: MolMed's Pipeline
  • Table 10.12: NeuroNova's Projects
  • Table 10.13: NewLink's Pipeline Overview
  • Table 10.14: OncoMed's Development Pipeline
  • Table 10.15: Vitoss Bone Graft Substitutes
  • Table 10.16: Osiris' Product Pipeline
  • Table 10.17: Pervasis' Pipeline
  • Table 10.18: Pluristem's Product Candidates Pipeline
  • Table 10.19: Proneuron's Pipeline
  • Table 10.20: RegeneRx's Pipeline/Clinical Trials
  • Table 10.21: RegeneRx's T β Peptide Research
  • Table 10.22: SanBio's Product Pipeline
  • Table 10.23: Sangamo's Product Pipeline
  • Table 10.24: StemCells' Broad Pipeline
  • Table 10.25: Stemline Therapeutics' Clinical Programs
  • Table 10.26: Stemline Therapeutics' Preclinical Programs
  • Table 10.27: Stratatech's Product Pipeline
  • Table A1.1: Comparison of Autologous and Allogeneic Stem Cell Therapy
Show More
Pricing
Get Notified
Email me when related reports are published